4 most recent filings and news items mentioning MBRX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MBRX/news?limit=20"
Pull MBRX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMoleculin reported positive interim results from its MIRACLE trial, showing Annamycin achieved three-fold higher complete remission rates than the control. Strong efficacy in a difficult patient population supports the company's path toward regulatory approval.
View filing at SEC.gov →Independent market research found oncologists reported 6 out of 7 likelihood to prescribe Annamycin for relapsed/refractory AML, citing efficacy, safety, and biomarker-agnostic use. Payers also expressed support for the drug as addressing significant unmet medical need in this pa
View filing at SEC.gov →Moleculin presented pooled analysis of 90 patients showing no detectable cardiotoxicity with Annamycin despite cumulative exposure levels far exceeding conventional anthracycline limits, with independent Cleveland Clinic validation. The positive cardiac safety data support the co
View filing at SEC.gov →Moleculin Biotech announced that pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting, showing no statistically significant cardiotoxicity at high cumulative doses. The findings support the pote
View filing at SEC.gov →